Livestock genetic engineering and precision breeding

01Overview and value chain#

Markers EC: FDA Guidance for Industry #187 (Intentionally Altered Genomic DNA in Animals) | OECD: Agricultural biotechnology | Regulator: FDA (USA), CFIA (Canada), MARA (China)

Livestock genetic engineering combines CRISPR-Cas9 gene editing with genomic selection to accelerate traits that classical breeding reaches only after many generations. Porcine Reproductive and Respiratory Syndrome (PRRS) alone costs US pork producers an estimated $1.2 billion a year, and a single exon deletion in the CD163 receptor gene removes the virus’s entry point without adding any foreign DNA. The US FDA issued its first low-risk determination for an intentionally altered genomic DNA (IGA) in cattle on March 7, 2022, covering two PRLR-edited “SLICK” lines; by 2025–2026 the same low-risk framework had cleared a heat-tolerance edit and a PRRS-resistance edit for commercial use, while Canada’s food-safety regulators completed an independent review in parallel. Research groups outside the big three regulatory blocs are moving in parallel: India’s first gene-edited farm animal, a myostatin-pathway-edited sheep, took a single university team roughly six years and near 400 embryo- transfer trials to confirm.

Key directions of livestock genetic engineering:

1. Disease-resistance editing (Disease-Resistance Gene Editing): single receptor-gene deletions (CD163 for PRRS) that block viral entry rather than boosting immunity, avoiding any transgene insertion.
2. Thermotolerance editing (Thermotolerance Gene Editing): introducing naturally occurring heat-tolerance alleles (PRLR-SLICK) from tropically adapted cattle breeds into high-yield dairy and beef lines via CRISPR-Cas9.
3. Genomic selection and sexed semen (Genomic Selection & Sexed Semen): SNP-chip genotyping of animals as young as ~6 months, paired with sex-sorted semen, that raises genetic gain without altering any genome.
4. Public-sector founder-animal programs (Public-Sector Gene Editing): university and national-institute programs in India and China producing the first confirmed gene-edited founder animals in each country, ahead of any national commercial-approval pathway.

Sectoral value chain#

[trait discovery] ──> [edit design] ──> [founder production] ──> [regulatory review]
                                                                        │
                                                                (risk-based
                                                                 determination)
                                                                        │
                                                                        ▼
[commercial herd] <─── [genomic selection] <─────────────────────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• CRISPR-Cas9 site-directed nucleases (CRISPR-Cas9 Site-Directed Nucleases): introduce single-base or short-exon edits that replicate existing natural alleles.
• Somatic cell nuclear transfer (Somatic Cell Nuclear Transfer): clones edited donor cells into enucleated oocytes to derive founder animals.
• SNP-chip genomic evaluation (SNP-Chip Genomic Evaluation): genome-wide marker panels that estimate breeding values without any gene editing.

02US#

The US holds the lead regulatory pathway: the FDA’s risk-based framework for intentionally altered genomic DNA in animals has cleared both a thermotolerance and a disease-resistance edit for the food supply.

FDA low-risk determinations, IGA guidance, genomic-selection adoption#

• FDA Guidance for Industry #187: the risk-based review track that classifies genomic alterations mirroring natural alleles as low-risk rather than requiring a full new-animal-drug approval.
• Acceligen PRLR-SLICK determination (March 7, 2022): the first FDA low-risk clearance for a gene-edited cattle line, covering two heat-tolerant lines and their offspring.
• Genomic selection at scale: US dairy herds routinely genotype heifers at roughly six months of age, combining SNP-chip evaluation with sexed and beef semen to raise genetic merit without any editing.

03CN#

China’s activity sits at the research stage: university groups are publishing CRISPR-edited livestock embryo work, while the national biosafety framework has not yet opened a commercial-approval pathway for gene-edited farm animals.

CRISPR dairy-cattle heat tolerance, MARA biosafety review, cloning-scale infrastructure#

• Inner Mongolia Agricultural University PRLR/SCNT program: CRISPR-Cas9 editing of a 20–150 bp region of the bovine PRLR gene, combined with somatic cell nuclear transfer, to study heat-stress resilience in dairy cow embryos.
• MARA biosafety review track: gene-edited animal research is evaluated case-by-case; unlike the US and Canada there is no standing commercial-approval pathway yet for gene-edited livestock products.
• Large-scale cloning infrastructure: China’s existing industrial-scale cattle-cloning capacity is an adjacent production base that gene-edited lines could eventually multiply through, once a commercial pathway opens.

04EU#

The EU proper still applies its pre-2001 GMO framework to gene-edited farm animals, while the UK has moved fastest among European jurisdictions with a dedicated precision-breeding regime and an FDA-adjacent commercial approval.

UK Precision Breeding Act, EU GMO-directive gap, swine disease-resistance R&D#

• Genus plc / PIC PRRS-resistant pig program: a CD163-exon deletion that blocks the PRRS virus’s cell-entry point; approved by the FDA on April 30, 2025, and by Health Canada and the CFIA on January 23, 2026.
• UK Precision Breeding Act (2023): enacted for plants first, with secondary legislation for precision-bred animals still pending as of 2026.
• EU Directive 2001/18 gap: the EU-27 continues to regulate gene-edited farm animals under its original GMO directive, with no dedicated animal precision-breeding pathway yet in force.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack pairs targeted gene editing with population-scale genomic evaluation.

1. CRISPR-Cas9 intentional genomic alterations (CRISPR-Cas9 IGAs):
   • edits replicate alleles that already occur naturally in some breeds rather than inserting foreign DNA.
   • case: the FDA classified the Acceligen PRLR edit as low-risk specifically because it mirrors the natural short-hair allele found in Criollo-derived cattle.
2. Somatic cell nuclear transfer (Somatic Cell Nuclear Transfer):
   • clones an edited donor cell’s nucleus into an enucleated oocyte to derive founder gene-edited embryos.
   • case: SKUAST-Kashmir needed roughly 400 embryo transfers over six years to confirm a single successfully edited lamb, illustrating SCNT’s low efficiency ceiling.
3. SNP-chip genomic selection (SNP-Chip Genomic Selection):
   • genome-wide marker genotyping estimates breeding values months before an animal’s own performance data exists.
   • case: US dairy heifers are genotyped at roughly six months of age on average, ahead of any breeding decision.

07Value chains and production pipelines#

Industrial pipeline of an intentional genomic alteration in livestock (FDA Guidance #187)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Trait/allele discovery │ ───> │ 2. Edit design & delivery │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Regulatory risk review │ <─── │ 3. Founder confirmation   │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Herd multiplication    │ ───> │ 6. Commercial deployment  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Trait/allele discovery

Breed surveys identify a naturally occurring resistance or tolerance allele — the PRLR short-hair allele in Criollo cattle, or the CD163 receptor variant that blocks PRRS entry.

Stage 2: Edit design & delivery

A CRISPR-Cas9 construct is designed to reproduce the natural allele, delivered by zygote microinjection or into a donor cell line for cloning.

Stage 3: Founder confirmation

Edited embryos are gestated to term and genotyped; SKUAST-Kashmir’s program needed close to 400 embryo transfers over six years to confirm one correctly edited lamb.

Stage 4: Regulatory risk review

A risk-based agency review compares the edited genome against natural variation; the FDA’s first cattle determination took from initial submission to a March 7, 2022 low-risk clearance.

Stage 5: Herd multiplication

SNP-chip genomic selection and sexed semen expand the edited line into a commercial-scale herd without further editing.

Stage 6: Commercial deployment

Processor and export-market acceptance is confirmed; as of 2026 no major US milk processor had yet committed to a branded price premium for gene-edited-line milk, even after full regulatory clearance.